ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients-Reference-Cited by-同舟云学术

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

Published:2016-02 Issue:2 Volume:35 Page:213-221
ISSN:1053-2498
Container-title:The Journal of Heart and Lung Transplantation
language:en
Short-container-title:The Journal of Heart and Lung Transplantation

Author:

Gottlieb Jens,Zamora Martin R.,Hodges Tony,Musk A.W.,Sommerwerk Urte,Dilling Daniel,Arcasoy Selim,DeVincenzo John,Karsten Verena,Shah Shaily,Bettencourt Brian R.,Cehelsky Jeffrey,Nochur Sara,Gollob Jared,Vaishnaw Akshay,Simon Amy R.,Glanville Allan R.

Publisher

Elsevier BV

Subject

Transplantation,Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference30 articles.

1. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients;Whimbey;Clin Infect Dis,1996

2. Community respiratory virus infections in immunocompromised patients with cancer;Whimbey;Am J Med,1997

3. Impact of respiratory virus infections on persons with chronic underlying conditions;Glezen;JAMA,2000

4. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study;Gottlieb;Transplantation,2009

5. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus;Hopkins;Am J Respir Crit Care Med,2008

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Description, clinical impact and early outcome of S. maltophilia respiratory tract infections after lung transplantation, A retrospective observational study;Respiratory Medicine and Research;2024-11

2. Direct-acting antivirals for RSV treatment, a review;Antiviral Research;2024-09

3. Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development;Reviews in Medical Virology;2024-08-29

4. Application of therapeutic nucleic acids and RNA interference to create products for personalised medicine;Biological Products. Prevention, Diagnosis, Treatment;2024-06-14

5. Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses;Antiviral Research;2024-06